Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on March 18, 2022, covering events occurring on March 14 and March 15, 2022. The Company is a Nevada corporation with its principal executive office in Boca Raton, Florida, and its common stock trades on the Nasdaq Global Select Market under the symbol TXMD.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Nasdaq Delisting Notice: On March 15, 2022, the Company received a determination letter from Nasdaq stating it failed to regain compliance with the Minimum Bid Price Requirement of $1.00 per share. The stock had not maintained a closing bid price of at least $1.00 for ten consecutive trading days during the 180-day compliance period granted in September 2021.
- Executive Departure: On March 14, 2022, James C. D'Arecca notified the Company of his resignation as Chief Financial Officer and Principal Financial Officer, effective April 1, 2022.
- Interim Appointment: Michael C. Donegan, Vice President – Finance and Chief Accounting Officer, was appointed as Interim Chief Financial Officer and Principal Financial and Accounting Officer effective April 1, 2022.
Guidance, Outlook, and Risks
Compliance Plan: The Company has requested a hearing before the Nasdaq Hearings Panel to appeal the delisting determination. Trading will remain suspended from removal pending the hearing outcome. Management intends to monitor the stock price and conduct a reverse stock split if necessary to regain compliance.
Management Transition: The Company plans to initiate a search for a permanent Chief Financial Officer, evaluating both internal and external candidates.
Risks: The filing highlights risks regarding the Company's ability to maintain its Nasdaq listing and the potential impact of management transitions on operations. Forward-looking statements are subject to uncertainties and are not guarantees of future performance.
Investor Verification Checklist
- Verify the status of the appeal hearing before the Nasdaq Hearings Panel and the expected timeline for a decision.
- Monitor the Company's announcement regarding the potential execution of a reverse stock split to meet the $1.00 minimum bid price.
- Review the progress of the search for a permanent Chief Financial Officer following the resignation of Mr. D'Arecca.
- Check subsequent filings for any updates on the Company's financial condition, as this 8-K does not contain financial data.